日本消化器外科学会雑誌第41巻第1号

日本化学療法学会雑誌第58巻第4号

Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p

日本化学療法学会雑誌第57巻第5号

in vitro Key words Streptococcus pneumoniae β Haemophilus influenzae Escherichia coli I Table. Antibacteriallevofloxacinactivityagainstclinicalisolates Organism Year Susceptibility(%)(Numberofstrains)

アルコール依存症

日本化学療法学会雑誌第57巻第S-2号

Key words β I Table. Observationandtestschedule Testschedule Observation/Tests Beforetreatment Endoftreatment 5 9days aftercompletion oftreatment 4 6weeks aftercompletion oftreatment Informedconsent Patientbackground

目　　　　次

1 2 3 t 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 IP 169 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67

日本化学療法学会雑誌第61巻第6号

β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

日本糖尿病学会誌第58巻第7号

l l l l β μ l l l l l l α l l l l l l l μ l l l α l l l l l μ l l l l l l l l l l l l l μ l l l l l β l μ l μ l μ l μ l l l l l μ l l l μ l l μ l l l α α l μ l l μ l α l μ l α l l l μ l l l μ l l μ l

17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas

17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] 1 3 30 VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas aeruginosa MRSA Acinetobacter species Enterobacter

４月号　学会特集号　１２２２４７／１６）一般演題目次

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68

info information mation info information mation info information mation info information mation info information mation info information mation info information mation info information mation info information

untitled

- 1 -

- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus

ヒビスコール液A カタログ

1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia

内科９６巻３号★／ＮＡＩ３‐１（第２２回試験問題）

µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

日本化学療法学会雑誌第64巻第4号

β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

Table 1 Epidemiologic characteristics in the elderly patients with sepsis Table 2 Main underlying disease

Key words: elderly patient, sepsis, multiple organ failure (MOF) Table 1 Epidemiologic characteristics in the elderly patients with sepsis 1985-1994 Table 2 Main underlying disease Fig. 1 The yearly frequency

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

日本化学療法学会雑誌第55巻第S-1号

µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius

院内感染対策相談窓口　質疑応答集（平成26年度）

Q MRSA -------------------------------- Q MRSA ------------------ Q ----------------------------------- Q -------------------------- Q --------------- Q ----------------------- Q ----------------------------

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

Fig. 1 Table l l l l l l l l l l l l l l l l l l l l l l l l l l

R06_01

Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2

untitled

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus

CHEMOTHERAPY

CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

ネットワークユーティリティ説明書

「東京都子供・子育て支援総合計画」中間見直し版（案）第2章　子供と家庭をめぐる状況

1 (1) (2) (3) (4) (5) (6) (7) (8) 2 (1) (2) (3) (4) (5) (6) (7) 10,000 100% 8,000 78.7% 78.1% 79.3% 78.3% 74.1% 75.4% 73.2% 80% 6,000 46.6% 47.5% 50.9% 51.5% 49.9% 51.8% 52.2% 60% 4,000 2,000 3,713

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc

4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97

H28_大和証券_研究業績_C本文_p indd

大腸癌周術期における腸内細菌叢の変化と術後創感染への影響に関する研究 聖路加国際病院消化器センター 副センター長大東誠司 はじめに近年 大腸癌は増加の一途を辿っており大腸癌の罹患率 死亡率は依然として増加傾向にある 大腸癌治療の根幹は外科的手術であり 5 年相対的生存率 75% 以上と比較的良好な成績といえる しかし大腸癌術後の感染症 なかでもsurgical site infection(ssi)

日本呼吸器学会雑誌第45巻第2号

ADL: Feeding Transfer Dressing Bathing IADL: Shopping Transportation Table1 Spector-KatzIndex * ADL-IADLisevaluatedbythesum ofeachscore(0:totaly dependent,6:totalyindependent) Table2 Generalcharacteristicsofthepatients

Key words: MRSA, Blood culture, TSST-1, Phage type, theory of quantification Table 1 Antibiotic resistant patterns of S. aureus isolated from blood cultures during 1984.1-1986.4 MRSA: methicillin-resistant

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

CHEMOTHERAPY

VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter

第５号（２００２年）／巻頭

Annual Report of Nagoya University School of Health Sciences K. pneumoniae Pseudomonas aeruginosa Proteus mirabillis MYH9 NMMHC A Thermus aquaticus

公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 3. 感染症発生率感染症発生件数の合計は 981 件であった 人工呼吸器関連肺炎の発生率が 1.5 件 / 1,000 患者 日 (499 件 ) と最も多く 次いでカテーテル関連血流感染症が 0.8 件 /

公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 集中治療室(ICU) 部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 集中治療室 (Intensive Care Unit : ICU) における人工呼吸器関連肺炎 尿路感染症 カテーテル関連血流感染症の発生状況 * を明らかにすることである 集計対象医療機関の各感染症発生率を 1,000 患者

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus

CHGエタノール消毒液１％製品情報_PDF

サラヤ株式会社 CHG エタノール消毒液 1% 製品情報 1/12 56-0260-00-04PDF サラヤ株式会社 CHG エタノール消毒液 1% 製品情報 2/12 56-0260-00-04PDF 目 次 1. はじめに 1 2. 特徴 2 3. 組成 性状 2 4. 効能 効果および用法 用量 2 5. 殺菌力 3 5-1 各種細菌 真菌に対する in vitro での殺菌力 5-2 持続殺菌力

E. coli E. coli é H. influenzae Helicobacter pylori

é C.pneumoniae C.trachomatis C.trachomatis 1 é Chlamydia pneumoniae Chlamydia psittaci Chlamydia trachomatis 3 E. coli E. coli é H. influenzae Helicobacter pylori K. pneumoniae L. monocytogenes ü l Staphylococcus

DIC vegetation 1 nonbacterial thrombogenic e

2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus

SCORE−‹Šp‡Ì”è‹ø‡«Ver3

2 Step 0 Step 1 Step 1 Step 2 Step 3 Step 4 Step 5 Step1 3 Step 2 Step 2-1 Step 2-2 Step3 Step4 Step2 4 5 Step 3 Step 3-1 Step 3-2 Step 3-3 Step5 6 Step 3-4 Step3 Step5 7 8 Step 4 Step 4-1 9 Step4 Step

600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12

untitled

Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004

????? 1

No. 42 OCT. 2010 Tel. 03-5215-2231 Fax. 03-5215-2232 http://www.nichidokyo.or.jp/ E-mail: jsla@nichidokyo.or.jp 4 6 9 12 16 20 24 28 32 35 38 41 43 44 45 46 LABIO 21 OCT. 2010 3 LABIO 21 OCT. 2010 4 LABIO

一般社団法人 日本感染症学会 第89回総会資料

Longitudinal surveillance of Haemophilus influenzae isolates from pediatric patients with meningitis throughout Japan, 2000 2011 Journal of Infection and Chemotherapy Vol.19No.1 p34-41kimiko Ubukata Long-term

Prenention of ventilator-associated pneumonia

Journal Club スペインにおける 国家規模の VAP 予防の取り組み 2018/03/20 大阪市立総合医療センター吉野智美 1 Critical Care Medicine 2018; 46(2): 181-188 Pneumonia Zero プロジェクトにより VAP の発症が 50% 以上減った 2 VAP にまつわる定義 2016 年のIDSA/ATSガイドラインでは HAP;

日本消化器外科学会雑誌第39巻第2号

Fig. Thenumberofcasesandtheage χ Table Patientscharacteristics (Aged8andover) Non-(A) (Agedintheirs) Non-(B) (Agedintheirs) Numberofcases Meanage(years) Gender;Male/Female Preoperativecomplications Cardiacmorbidity

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

基発0408第2号 東日本大震災に伴う解雇、雇止め等に対する対応について

Acecide_ProductsInformation2010PDF.indd

53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =

日本化学療法学会雑誌第65巻第4号

531 総説 Key words: Staphylococcus aureus Streptococcus pneumoniae β Haemophilus influenzae Mycoplasma pneumoniae 532 日本化学療法学会雑誌 J U L Y 2 0 1 7 I. 抗菌薬の現状を考える 1. 抗菌薬開発の動向 No. of NDA approvals 40 35 30 25

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

04-c-„FŒ{›xŒ¾-4.01

544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli

日本化学療法学会雑誌第57巻第1号

In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli

日本化学療法学会雑誌第57巻第4号

Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.

IP S ( :H ) ( ) ( :H22 4

90 30 440 8515 4 101 0532 54 5111 0532 53 1379 IP 1. 2. 3. 11 1 1. 2. 12 0 1 2 3 8 0 8 0 8 S 5 5 0 5 2 1 13 0 5 0 4 (:H22 4 28 ) 1 1 0 5 () (:H22 4 28 ) 1 2 5 0 (: ) ー (: ) ー1 0 0 0 0 (: ) 1/26 50P7 21

VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

in situ Hex

in situ Hex Sox Sox17Sox18 Sry Sox9 Sox17 Hex Hex N Drosophila O The 5th Conference on ABC Proteins and Ion Channels From Gene to Disease The 5th Conference on ABC Proteins and Ion Channels From Gene

Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,

Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates

日本臨床微生物学雑誌第22巻第3号

2012 STEC 231 3 STEC 1) 1) 1) 2) 2) 3) 1) 2) 3) 24 3 6 24 7 19 (Enterohemorrhagic Escherichia coli; EHEC) STEC XM-EHEC 5S A /ViEHEC O157, O26, O111 3 STEC, 14.2 100, XM-EHEC, 7.1 85.7, ViEHEC, 27.6 100

TABLE of CONTENTS 11 51 65 187 1 2 3 4 5 6 é é 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum

Jpn. I. Oral Biol., 37: , Antimicrobial effects of high oxidation potential water on various microorganisms and an evaluation of mutageni

Jpn. I. Oral Biol., 37: 152-161, 1995. Antimicrobial effects of high oxidation potential water on various microorganisms and an evaluation of mutagenicity of the water Shojiro Asai, Masatsugu Yamamura,

川名 430 Fig.1 (a) Compressor jet-nebulizer Using the with nasal (Devilbiss nasal inhalation inhalation Pulmo-Aide) and 明彦 他 Fig.2 equipment.(b) Process

Key words:povidone-iodine,nasal inhalation,pharyngeal colonization 川名 430 Fig.1 (a) Compressor jet-nebulizer Using the with nasal (Devilbiss nasal inhalation inhalation Pulmo-Aide) and 明彦 他 Fig.2 equipment.(b)

JC46601’ÓFC

6 1 Active Infective Endocarditis Remaining Latent for Six Weeks After Discontinuation of Antibiotic Therapy: A Case Report Ayumu Kazuhito Masamitsu Masanori Motonobu Masaaki Haruhiko Koetsu Yuichi Shigeyuki

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical

第65回日本化学療法学会東日本支部総会 抄録

鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

2.7 臨床概要

2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331

Table 1 Comparsion of background of the 86 patients with colorectal perforation All Survival Death p-value No. of patients 86 (100%) 74 (86%) 12 (14%)

Japanese Journal of Acute Care Surgery 2013; 3: 55~60 原著 非外傷性大腸穿孔 86 症例の臨床的検討 上田健太郎岩﨑安博山添真志川副友川嶋秀治國立晃成酒谷佳世山上裕機加藤正哉 x 所属 : 和歌山県立医科大学救急集中治療医学講座住所 : 641-8510 和歌山県和歌山市紀三井寺 811-1 Table 1 Comparsion of background

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

02-(a)-Łi’ì™·Łv-4.11

THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus

PET-CT

.{...book

14 9 10 9 12 9 12 3 44.1.12 13 90 90 42. 5.6 90 44.1.12 14 9 11 14 9 14 1 2 27 4 3 1 214 60 10 51662 3 1034 9 2987 11 2998 1 309 3 3110 3 30 510 12 14 2 8 B OB 43.7.19 27 6 2 9 26 7 18 4 5 6 7 8 9 10 11

JAN Fig. 1 Effect of storage on CEC solution (Thin layer cup method B. subtilis PCI-219)

272 @ CHEMOTHERAPY @ JAN. 1976 Fig. 1 Effect of storage on CEC solution (Thin layer cup method B. subtilis PCI-219) VOL. 24 NO. 1 CHEMOTHERAPY @ 273 Fig. 2 Effect of dilution with phosphate buffer on bile

Key words: septic shock, Klebsiella pneumoniae, corticosteroid

Key words: septic shock, Klebsiella pneumoniae, corticosteroid 馬 場 ます み 他 490 Table 1 Laboratory findings Fig. 1 on admission The circle Fig. 2 Table 2 血 球 減 少,血 Laboratory findings connects Chest Hemodynamic

上野久美子 他 354 は 高 齢 者 入 院 患 者 の 発 熱 初 期 に お け る病 態 を把 握 し 適 切 な 治 療 が 行 え る よ う に,発 protein 1 Duration of febrile episodes 熱 の 原 因 疾 患, 発 熱 初 日 の 最 高 体

Key words: elderly, febrile episode, nosocomial infection 上野久美子 他 354 は 高 齢 者 入 院 患 者 の 発 熱 初 期 に お け る病 態 を把 握 し 適 切 な 治 療 が 行 え る よ う に,発 protein 1 Duration of febrile episodes 熱 の 原 因 疾 患, 発 熱 初 日 の

( 23 )

( 23 ) 2 9 11 16 21........................................... 21........................................... 24........................................... 28...........................................

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

第26回日本環境感染学会総会プログラム・抄録集　Part1

26 26 26 26 26 2009 Klebsiella pneumoniae producing carbapenemasekpcmulti-drug resistant Acinetobacter baumannii MDRAbNew Delhi Metallo--Lactamase-1NDM-1 WHO CDC John BoyceDidier Pittet William RutalaCLA-BSIMark

Key words: infection stone, biofilm, urease, glycocalyx

Key words: infection stone, biofilm, urease, glycocalyx 740 林 俊秀 Fig. 1 SEM of cut surface of urinary stones: (a) S. epidermidis biofilm embedded in apatite bladder stone (Group I), (b) K. Pneumonia and